Disappointment for Australian pharma as govt snubs stability deal
This article was originally published in SRA
Executive Summary
Medicines Australia has expressed its disappointment at the decision by the country's health minister not to sign a strategic agreement that would have provided the Australian R&D-based pharmaceutical industry with some policy stability over the next five years in return for it agreeing to support medicines access and sustainability measures including price cuts to medicines listed on the Pharmaceutical Benefits Scheme.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.